

MEMBERS PRESENT

Dr. Montgomery McInturff, Board of Veterinary Medicine,
Dr. Bhekumuzi Khumalo, Podiatry Board
Dr. Kurt Steele, Board of Optometry
Ms. Sheryl Wright, Board of Nursing
Mr. Jake Bynum, Board of Pharmacy Public Member
Mr. James Diaz Barriga, Board of Medical Examiner Public Member

STAFF PRESENT

Dr. Pete Phillips, Director of Controlled Substance Monitoring Database
Mr. Justin Harleman, Attorney, Office of General Counsel
Ms. Debora Sanford, Clinical Application Coordinator
Ms. Tracy Bacchus, Administrative Assistant

MEMBERS ABSENT

Mr. Robert Ellis, Board of Medical Examiners
Dr. Adam Rodgers, Board of Pharmacy
Dr. Robert Caldwell, Board of Dentistry
Dr. Shant Garabedian, Osteopathic Board, Chairperson
Mr. Robert White, Committee on Physician Assistants, Vice Chairperson
Dr. John McGraw, Board of Medical Examiners

The Controlled Substance Monitoring Database (CSMD) Committee convened via Webex on Tuesday, February 21, 2023, and in the Iris Room, 665 Mainstream, Nashville, TN. Dr. Bhekumuzi Khumalo called the meeting to order at 9:00 a.m. and there was a roll call introduction.

CSMD Director's Report – Dr. Pete Phillips

- Key Analytical Findings comparing 2015-2022
 - Morphine Milligram Equivalents (MME) prescribed and dispensed to patients in TN has decreased by 60%.
 - Number of potential doctor shoppers has decreased by 92%.
 - Number of opioid prescriptions for pain has decreased by 44%
- Key Highlights for CSMD in 2022
 - The number of controlled substance prescriptions reported to the CSMD continues to decrease.
 - Response time for searches in the CSMD was less than one second if the request did not include data from another state.
 - Gateway integration with Electronic Health Record (EHR) and Pharmacy Management System workflows has been widely adopted across the state enabling users to provide more direct-to-patient care.
 - CSMD is embracing connections to the RxCheck Hub, a federally supported PDMP data sharing system that supports interstate data sharing and EHR integration.
- Considerations Related to Overdose Data
 - Fatal drug overdoses in TN have increased rapidly, exacerbated by the effects of the COVID-19 pandemic. While increases in overdoses continue to be primarily related to illicit substances such as fentanyl and methamphetamine, inappropriate use of prescription drugs still poses a major risk to Tennesseans.

- Opioids typically obtained through a prescription for pain relief were involved in 645 overdose deaths in 2021, an 8% increase from 2020.
- Among all opioid-related overdose deaths in 2021, 17% also involved benzodiazepines, highlighting the critical importance of avoiding concomitant use of opioids and benzodiazepines.
- In 2021, 45% who died of drug overdose involving opioids and benzodiazepines had any controlled substance dispensed within 60 days of death. Among people who died of an overdose involving pain relievers, only 30% had an opioid prescription. Among those who died of an overdose involving benzodiazepines, only 34% had a benzodiazepine prescription within 60 days of death. This reinforces the need for a three-pronged approach of prevention, treatment, and enforcement in improving the epidemic.
- Number of Registrants in the CSMD, 2015-2022
 - 2015 was 42,835
 - 2022 was 64,717
- Doctor and Pharmacy Shopper decreased to 92% since 2015
- Top 10 Most Frequently Prescribed Controlled Substances Reported to CSMD, for 2022*

Name of Drug	Number of RX	Percent (%)
Gabapentin	2,090,488	18.5
Hydrocodone	2,003,169	17.7
Oxycodone	1,510,853	13.4
Alprazolam	1,161,778	10.3
Amphetamine	1,066,637	9.4
Buprenorphine	904,587	8.0
Zolpidem	708,666	6.3
Tramadol	686,600	6.1
Clonazepam	645,050	5.7
Phentermine	537,669	4.8

*Not including the prescriptions reported from VA pharmacies. Products were identified based on a combination of CDC document and RedBook file.

- Gateway Electronic Health Record (EHR)/Pharmacy System Integration Project
 - Throughout 2022, the CSMD has experienced a significant increase in the number of healthcare providers that are integrated with Gateway.
 - Of the healthcare providers using Gateway, many independent practices experience efficiencies in their workflow to meet statutory regulations of the CSMD with no added financial burden.
 - In order to offer the healthcare providers a no-cost state-wide connection to the Gateway service, the CSMD has received funding from the State prescribing boards for human patients and the Board of Pharmacy until June 30, 2023.
 - Additional funding sources are being sought from programs such as the Opioid Abatement Council to continue this exceptional service throughout the remainder of 2023.

- Dr. Bhukumuzi Khumalo asked the committee for a motion to approve the 2023 CSMD Legislative Report.
 - Dr. James Venable made the motion to approve the 2023 CSMD Legislative Report, and Ms. Sheryl Wright seconded the motion.
 - 2023 CSMD Legislative Report were approved by roll call vote.

The meeting adjourned by roll call vote at 9:30 a.m.